Fulcrum TherapeuticsFULC
About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Employees: 89
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
254% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $7.19M
24% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 34
6% more funds holding
Funds holding: 121 [Q2] → 128 (+7) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 35
18.25% less ownership
Funds ownership: 106.32% [Q2] → 88.07% (-18.25%) [Q3]
52% less capital invested
Capital invested by funds: $410M [Q2] → $197M (-$213M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for FULC.
Financial journalist opinion









